Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study
Jianliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Shiyu Jiang(Second Affiliated Hospital of Zhejiang University), Haifeng Song(Anhui Medical University), Sheng Yang(Fujian Medical University), Sheng Yao(BioReliance (United States)), Jiarui Yao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Sun(Peking University), Peng Liu(Jiangxi University of Traditional Chinese Medicine), Lihou Dong(Academy of Military Medical Sciences), Ying Han(Fujian University of Traditional Chinese Medicine), Shuxiang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhishang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hai Wu, Hui Feng(Boston University)
Cited by 70
Related Papers
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934